ActiveFX™ is backed by over two decades of clinical data, thousands of successful procedures by Dr. Glenn DeBias, and hundreds of peer-reviewed studies on the Lumenis UltraPulse® platform.
Since its development by Dr. DeBias in 2004, the ActiveFX™ protocol has become the benchmark for fractional CO2 laser resurfacing worldwide. Clinical literature consistently demonstrates its superior ability to remodel collagen, improve texture, and reduce photodamage.
Dr. DeBias has personally performed over 18,000 fractional CO2 treatments, making him one of the most experienced laser physicians globally.
Clinical tracking shows an average downtime of just 3.5 days for ActiveFX™, compared to weeks for traditional fully ablative resurfacing.
Histological studies confirm that new collagen formation triggered by ActiveFX™ continues for up to 6 months post-procedure.
Prospective studies demonstrate statistically significant improvement in fine lines, deep wrinkles, and overall skin texture after a single ActiveFX™ treatment, utilizing the 1.3mm spot size for optimal epidermal renewal.
Clinical trials show DeepFX™ (0.12mm spot size) and SCAARFX™ modes provide 50-75% improvement in atrophic acne scars and severe burn contractures, reaching depths of up to 4.0mm.
ActiveFX™ effectively clears actinic damage and sun spots, restoring an even, radiant skin tone with high patient satisfaction scores.
ActiveFX™ was originally developed and optimized using the Lumenis UltraPulse® laser system—widely regarded as the most powerful and versatile CO2 laser in aesthetic medicine.
With its proprietary SuperPulse technology, the platform delivers ultra-short, high-peak-power energy that ablate tissue faster than it conducts heat. This exceptional ablation-to-coagulation ratio minimizes collateral thermal damage while maximizing results.
Explore UltraFrax™ Technology